心房颤动抗凝患者并发症的管理
Management of Complications in Anticoagulated Patients with Atrial Fibrillation.
作者信息
Katritsis George D, Katritsis Demosthenes G
机构信息
Imperial College Healthcare NHS Trust,London, UK.
Hygeia Hospital,Athens, Greece.
出版信息
Arrhythm Electrophysiol Rev. 2017 Dec;6(4):167-178. doi: 10.15420/aer.2017.23.1.
Abstract
Oral anticoagulation is mandatory for patients at high risk of thromboembolism, but the risk of bleeding should also be taken into account. Direct oral anticoagulants are now recommended for non-valvular AF as a potential alternative to warfarin. In this article we discuss methods to assess the anticoagulant effect of these agents, specific and general antidotes, and management of complications such as embolic and haemorrhagic stroke, and significant bleeding.
摘要
对于有高血栓栓塞风险的患者，口服抗凝治疗是必需的，但也应考虑出血风险。目前推荐直接口服抗凝剂用于非瓣膜性房颤，作为华法林的潜在替代药物。在本文中，我们讨论评估这些药物抗凝效果的方法、特异性和非特异性解毒剂，以及栓塞性和出血性中风等并发症及严重出血的管理。
相似文献
1
Management of Complications in Anticoagulated Patients with Atrial Fibrillation.心房颤动抗凝患者并发症的管理
Arrhythm Electrophysiol Rev. 2017 Dec;6(4):167-178. doi: 10.15420/aer.2017.23.1.
2
Use of oral anticoagulants in complex clinical situations with atrial fibrillation.在伴有房颤的复杂临床情况下使用口服抗凝药物。
Med Clin (Barc). 2018 Jun;150 Suppl 1:8-24. doi: 10.1016/S0025-7753(18)30666-3.
3
Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials.新型口服抗凝剂与华法林治疗心房颤动患者的疗效和安全性比较：随机试验的荟萃分析。
Lancet. 2014 Mar 15;383(9921):955-62. doi: 10.1016/S0140-6736(13)62343-0. Epub 2013 Dec 4.
4
Novel Oral Anticoagulants in Direct Current Cardioversion for Atrial Fibrillation.新型口服抗凝药在心房颤动直流电复律中的应用
Heart Lung Circ. 2018 Jul;27(7):798-803. doi: 10.1016/j.hlc.2017.06.726. Epub 2017 Jul 17.
5
Risk factors for thromboembolic and bleeding events in anticoagulated patients with atrial fibrillation: the prospective, multicentre observational PREvention oF thromboembolic events - European Registry in Atrial Fibrillation (PREFER in AF).心房颤动抗凝治疗患者血栓栓塞和出血事件的风险因素：前瞻性、多中心观察性预防血栓栓塞事件-心房颤动欧洲登记研究（PREFER in AF）。
BMJ Open. 2019 Mar 30;9(3):e022478. doi: 10.1136/bmjopen-2018-022478.
6
New oral anticoagulants for atrial fibrillation: a review of clinical trials.新型口服抗凝药物在心房颤动中的应用：临床试验研究综述。
Clin Ther. 2012 Apr;34(4):894-901. doi: 10.1016/j.clinthera.2012.01.019. Epub 2012 Mar 13.
7
Novel oral anticoagulants for the prevention of thromboembolism in patients with atrial fibrillation.新型口服抗凝药用于预防心房颤动患者的血栓栓塞。
J R Coll Physicians Edinb. 2013;43(2):151-8. doi: 10.4997/JRCPE.2013.213.
8
Anticoagulation in women with non-valvular atrial fibrillation in the stroke prevention using an oral thrombin inhibitor (SPORTIF) trials.在使用口服凝血酶抑制剂预防卒中（SPORTIF）试验中，非瓣膜性心房颤动女性的抗凝治疗。
Eur Heart J. 2006 Aug;27(16):1947-53. doi: 10.1093/eurheartj/ehl103. Epub 2006 Jun 14.
9
Thromboembolism and bleeding in patients with atrial fibrillation and liver disease - A nationwide register-based cohort study: Thromboembolism and bleeding in liver disease.房颤合并肝脏疾病患者的血栓栓塞和出血事件 - 一项全国范围内基于登记的队列研究：肝脏疾病中的血栓栓塞和出血事件。
Clin Res Hepatol Gastroenterol. 2022 Oct;46(8):101952. doi: 10.1016/j.clinre.2022.101952. Epub 2022 May 21.
10
Can Direct Oral Anticoagulants Be Used for Stroke Prevention Among Patients with Valvular Atrial Fibrillation?直接口服抗凝剂可否用于预防瓣膜性心房颤动患者的卒中？
Curr Cardiol Rep. 2019 Aug 31;21(10):118. doi: 10.1007/s11886-019-1199-4.
本文引用的文献
1
Screening for Atrial Fibrillation: A Report of the AF-SCREEN International Collaboration.心房颤动筛查：AF-SCREEN 国际合作研究报告。
Circulation. 2017 May 9;135(19):1851-1867. doi: 10.1161/CIRCULATIONAHA.116.026693.
2
2017 AHA/ACC Focused Update of the 2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.2017年美国心脏协会/美国心脏病学会对2014年《美国心脏协会/美国心脏病学会瓣膜性心脏病患者管理指南》的重点更新：美国心脏病学会/美国心脏协会临床实践指南工作组报告
Circulation. 2017 Jun 20;135(25):e1159-e1195. doi: 10.1161/CIR.0000000000000503. Epub 2017 Mar 15.
3
Use of Intravenous Recombinant Tissue Plasminogen Activator in Patients With Acute Ischemic Stroke Who Take Non-Vitamin K Antagonist Oral Anticoagulants Before Stroke.急性缺血性脑卒中患者在卒中前使用非维生素 K 拮抗剂口服抗凝剂时的静脉重组组织型纤溶酶原激活剂的应用。
Circulation. 2017 Mar 14;135(11):1024-1035. doi: 10.1161/CIRCULATIONAHA.116.023940. Epub 2017 Jan 24.
4
2017 ACC Expert Consensus Decision Pathway for Periprocedural Management of Anticoagulation in Patients With Nonvalvular Atrial Fibrillation: A Report of the American College of Cardiology Clinical Expert Consensus Document Task Force.2017 年美国心脏病学会专家共识决策路径：非瓣膜性心房颤动患者抗凝治疗围术期管理：美国心脏病学会临床专家共识文件工作组的报告。
J Am Coll Cardiol. 2017 Feb 21;69(7):871-898. doi: 10.1016/j.jacc.2016.11.024. Epub 2017 Jan 9.
5
Guideline for Reversal of Antithrombotics in Intracranial Hemorrhage: Executive Summary. A Statement for Healthcare Professionals From the Neurocritical Care Society and the Society of Critical Care Medicine.颅内出血抗栓药物逆转指南：执行摘要。神经重症监护学会和危重症医学会给医疗专业人员的声明。
Crit Care Med. 2016 Dec;44(12):2251-2257. doi: 10.1097/CCM.0000000000002057.
6
Wide Variation in Reported Rates of Stroke Across Cohorts of Patients With Atrial Fibrillation.心房颤动患者队列中报告的卒中发生率存在广泛差异。
Circulation. 2017 Jan 17;135(3):208-219. doi: 10.1161/CIRCULATIONAHA.116.024057. Epub 2016 Oct 31.
7
Genetic Risk Prediction of Atrial Fibrillation.心房颤动的遗传风险预测
Circulation. 2017 Apr 4;135(14):1311-1320. doi: 10.1161/CIRCULATIONAHA.116.024143. Epub 2016 Oct 28.
8
Andexanet Alfa for Acute Major Bleeding Associated with Factor Xa Inhibitors.安达西尼α用于治疗与Xa因子抑制剂相关的急性大出血。
N Engl J Med. 2016 Sep 22;375(12):1131-41. doi: 10.1056/NEJMoa1607887. Epub 2016 Aug 30.
9
Management of Bleeding With Non-Vitamin K Antagonist Oral Anticoagulants in the Era of Specific Reversal Agents.在特异性逆转剂时代，非维生素K拮抗剂口服抗凝剂所致出血的管理
Circulation. 2016 Jul 19;134(3):248-61. doi: 10.1161/CIRCULATIONAHA.116.021831.
10
Urgent Need to Measure Effects of Direct Oral Anticoagulants.迫切需要衡量直接口服抗凝剂的效果。
Circulation. 2016 Jul 19;134(3):186-8. doi: 10.1161/CIRCULATIONAHA.116.022307.
Zotero 插件